NCT06172088View on ClinicalTrials.gov

Exploratory Study Therapeutic Fasting Reduce Physical Limitations, Quality of Life During Aromatase Inhibitor Therapy

NAActive, not recruitingINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

December 15, 2023

Primary Completion Date

December 30, 2024

Study Completion Date

September 30, 2025

Conditions
Breast Cancer Patients Treated With Aromatase Inhibitors
Interventions
OTHER

Fasting

Sieben days of online supervised prolonged therapeutic fasting (max. 350 kcal/d).

Trial Locations (2)

70341

Robert-Bosch-Krankenhaus, Stuttgart

97080

Würzburg University, Würzburg

All Listed Sponsors
collaborator

Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF)

OTHER

collaborator

Charite University, Berlin, Germany

OTHER

lead

University Hospital Tuebingen

OTHER

NCT06172088 - Exploratory Study Therapeutic Fasting Reduce Physical Limitations, Quality of Life During Aromatase Inhibitor Therapy | Biotech Hunter | Biotech Hunter